[1]鞠迪李汨韩曼房冰莹闫曙光安荣李京涛.益脾养肝方对肝癌前病变大鼠肝星状细胞活化的影响[J].陕西中医药大学学报,2024,(02):083-88.[doi:10.13424/j.cnki.jsctcm.2024.02.016]
　JU Di LI MiHAN ManFANG BingyingYAN ShuguangAN Rong?LI Jingtao.Effect of Yipi Yanggan Formula on the Activation of Hepatic Stellate Cells inRats with Pre Liver Cancer Lesions[J].Journal of Shaanxi University of Traditional Chinese Medicine,2024,(02):083-88.[doi:10.13424/j.cnki.jsctcm.2024.02.016]
点击复制

益脾养肝方对肝癌前病变大鼠肝星状细胞活化的影响()
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2024年02期
页码:
083-88
栏目:
出版日期:
2024-03-20

文章信息/Info

Title:
Effect of Yipi Yanggan Formula on the Activation of Hepatic Stellate Cells inRats with Pre Liver Cancer Lesions
文章编号:
2096-1340(2024)02-0083-06
作者:
鞠迪1李汨1韩曼1房冰莹1闫曙光1安荣1李京涛2
1. 陕西中医药大学，陕西 咸阳 712046；
2.陕西中医药大学附属医院，陕西 咸阳 712000
Author(s):
JU Di1 LI Mi1HAN Man1FANG Bingying1YAN Shuguang1AN Rong1?LI Jingtao2
1.Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712046,China;
2.Affiliated Hospital of Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712000,China
关键词:
关键词：肝癌前病变; 益脾养肝方; 肝星状细胞; α-平滑肌动蛋白; 胶原沉积
Keywords:
Key words： Precancerous lesions of liver cancer; Yipi Yanggan formula; Hepatic stellate cells; α-Smooth actin; Collagen deposition
分类号:
R256.4
DOI:
10.13424/j.cnki.jsctcm.2024.02.016
文献标志码:
A
摘要:
摘要：目的 探讨益脾养肝方对二乙基亚硝胺（Diethylnitrosamine，DEN）诱导的肝癌前病变中肝星状细胞活化及胶原沉积的影响。方法 将26只雄性Sprague-Dawley大鼠随机分为空白组、模型组、益脾养肝方组和护肝片组，空白组5只，其余3组各7只。腹腔注射DEN诱导肝癌前病变模型，给药14 w后处死。取肝组织观察并记录其大小、外观等变化，计算肝重比（肝脏指数），通过HE染色观察大鼠肝组织病理形态学改变，天狼星红染色观察各组胶原沉积表达，免疫组化检测α-平滑肌动蛋白（alpha smooth muscle actin，α-SMA）的表达，实时定量PCR（Real Time PCR，RT-PCR）检测Ⅰ型胶原蛋白（type Ⅰ collagen，Collagen Ⅰ）的表达，以研究益脾养肝方对大鼠肝癌前病变模型的影响。计量资料多组间比较采用单因素方差分析，进一步两两比较采用LSD-t检验。结果 与模型组相比，益脾养肝方组和护肝片组肝脏病理形态显著改善，肝脏指数、Collagen Ⅰ和α-SMA表达均降低（P值均＜0.05）；与护肝片组相比，益脾养肝方组对肝脏的保护作用更显著，其肝脏指数、Collagen Ⅰ和α-SMA表达均显著降低（P值均＜0.05）。结论 益脾养肝方可有效改善DEN诱导的大鼠肝癌前病变，其机制可能与抑制肝星状细胞活化，减少胶原沉积有关。
Abstract:
Abstract： Objective To explore the effects of Yipi Yanggan formula on the activation of hepatic stellate cells and collagen deposition in diethylnitrosamine (DEN) induced precancerous lesions of liver cancer.Methods 26 male Sprague Dawley rats were randomly divided into a blank group,a model group,a Yipi Yanggan formula group,and a Hugan tablet group.There were 5 rats in the blank group and 7 rats in each of the other 3 groups.Den was injected intraperitoneally to induce a model of liver cancer precancerous lesions,and was euthanized after 14 weeks of administration.Take liver tissue for observation and record changes in size,appearance,etc.,calculate liver weight ratio (liver index),observe pathological and morphological changes in rat liver tissue through HE staining,observe collagen deposition and expression in each group through Sirius red staining,detect the expression of alpha smooth muscle actin (α-SMA) through immunohistochemistry,and detect type Ⅰ collagen (Collagen Ⅰ) through real-time quantitative PCR (RT-PCR) To investigate the effect of Yipi Yanggan formula on the pre liver cancer lesion model in rats.Multiple inter group comparisons of quantitative data were conducted using one-way analysis of variance,and further pairwise comparisons were conducted using LSD-t test.Results Compared with the model group,the liver pathological morphology of the Yipi Yanggan formula group and the Hugan tablet group was significantly improved,and the liver index,Collagen I,and α-SMA expression were all reduced (P<0.05);Compared with the liver protection tablet group,the Yipi Yanggan formula group has a more significant protective effect on the liver,with significantly reduced liver index,Collagen I,and α-SMA expression (P<0.05).Conclusion Yipi Yanggan formula can effectively improve DEN induced precancerous lesions in rats,and its mechanism may be related to inhibiting hepatic stellate cell activation and reducing collagen deposition.

参考文献/References:

［1］Goh GBB,Chang PE,Tan CK.Changing epidemiology of hepatocellular carcinoma in Asia［J］.Best Practice &?Research Clinical Gastroenterology,2015,29(6):919-928.
［2］焦俊喆,李京涛,闫曙光,等.肝细胞癌癌前异型增生结节的研究现状［J］.临床肝胆病杂志,2017,33(5):974-978.
［3］Liu BY,Zhou ZW,Jin Y,et al.Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of?liver cirrhosis toward hepatocellular carcinoma［J］.Journal for Immunotherapy of Cancer,2022,10(1):e003069.
［4］Shiraha H,Iwamuro M,Okada H.Hepatic stellate cells in liver tumor［J］.Advances in Experimental Medicine and Biology,2020,1234:43-56.
［5］杨粒,钱保林,付文广,等.活化的肝星状细胞参与肝细胞性肝癌发生发展的研究进展［J］.中国普通外科杂志,2022,31(1):116-122.
［6］Appunn S,Rubens M,Ramamoorthy V,et al.Lumican,pro-tumorigenic or anti-tumorigenic:a conundrum［J］.Clinica Chimica Acta,2021,514:1-7.
［7］Scheau C,Badarau IA,Costache R,et al.The?role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma［J］.Analytical Cellular Pathology (Amsterdam),2019,2019:9423907. 2019,9(1):83.
［8］Mazza G,Telese A,Al-Akkad W,et al.Cirrhotic human liver extracellular matrix 3D scaffolds promote smad-dependent TGF-β1 epithelial mesenchymal transition［J］.Cells,2019,9(1):E83.
［9］Wang PW,Lin TY,Yang PM,et al.Hepatic stellate cell modulates the immune microenvironment in the progression of hepatocellular carcinoma［J］.International Journal of Molecular Sciences,2022,23(18):10777.
［10］Hsieh CC,Hung CH,Chiang MH,et al.Hepatic stellate cells enhance liver cancer progression by inducing myeloid-derived suppressor cells through interleukin-6 signaling［J］.International Journal of Molecular Sciences,2019,20(20):E5079.
［11］Kew MC.The role of cirrhosis in the etiology of hepatocellular carcinoma［J］.Journal of Gastrointestinal Cancer,2014,45(1):12-21.
［12］Ruan Q,Wang HL,Burke LJ,et al.Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma［J］.International Journal of Cancer,2020,147(6):1519-1527.
［13］鞠迪,李汨,韩曼,等.益脾养肝方对大鼠肝癌前病变肝干细胞恶性转化的影响和作用机制［J］.临床肝胆病杂志,2022,38(4):865-871.
［14］宋春荣,南然,刘永刚,等.益脾养肝方对肝郁脾虚证原发性肝癌TACE患者bFGF、VEGF、AFP-L3及免疫功能影响［J］.辽宁中医药大学学报,2022,24(1):80-84.
［15］边倩,曹妮,刘航,等.益脾养肝方对大鼠肝癌癌前病变miR-221表达的影响［J］.陕西中医,2020,41(11):1515-1519.
［16］魏海梁,曹妮,李京涛,等.基于miRNA-124探讨益脾养肝方对大鼠肝癌前病变影响的实验研究［J］.陕西中医药大学学报,2020,43(5):60-65.
［17］李京涛,魏海梁,闫曙光,等.益脾养肝方对肝癌前病变大鼠血清IL-6、TNF-α的影响［J］.现代中西医结合杂志,2018,27(3):236-239.
［18］李京涛,闫曙光,魏海梁,等.益脾养肝方对大鼠肝癌癌前病变NF-κB、STAT3蛋白表达的影响［J］.辽宁中医杂志,2018,45(1):196-198,231.
［19］吴孟超,汤钊猷,刘彤华,等.原发性肝癌规范化病理诊断指南(2015年版)［J］.临床肝胆病杂志,2015,31(6):833-839.
［20］吴杰,李京涛,魏海梁,等.microRNA调控肝星状细胞活化干预肝癌癌前病变的研究进展［J］.临床肝胆病杂志,2020,36(7):1650-1654.
［21］Garrido A,Djouder N.Cirrhosis:a questioned risk factor for hepatocellular carcinoma［J］.Trends in Cancer,2021,7(1):29-36.
［22］Luo NA,Li JB,Wei Y,et al.Hepatic stellate cell:a double-edged sword in the liver［J］.Physiological Research,2021,70(6):821-829.［23］Khomich O,Ivanov AV,Bartosch B.Metabolic hallmarks of hepatic stellate cells in liver fibrosis［J］.Cells,2019,9(1):24.
［24］Li Y,Kim BG,Qian S,et al.Hepatic stellate cells inhibit T cells through active TGF-β1 from a cell surface-bound latent TGF-β1/GARP complex［J］.Journal of Immunology,2015,195(6):2648-2656.
［25］Wu MN,Miao HJ,Fu R,et al.Hepatic stellate cell:a potential target for hepatocellular carcinoma［J］.Current Molecular Pharmacology,2020,13(4):261-272.
［26］Lin N,Meng LL,Lin JZ,et al.Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietin-1［J］.Journal of Cellular Biochemistry,2020,121(2):1441-1451.
［27］彭佩纯,欧和生,罗雪兰,等.活化的肝星状细胞对肝癌肿瘤微环境的影响［J］.广西医学,2019,41(24):3184-3188.
［28］Lee KM,Nam K,Oh S,et al.ECM1 regulates tumor metastasis and CSC-like property through stabilization of β-catenin［J］.Oncogene,2015,34(50):6055-6065.
［29］鄂志野,文怡欣,张珊,等.基于数据库分析COL1A2在肝细胞癌组织中的表达及对预后的影响［J］.牡丹江医学院学报,2022,43(1):31-34,118.

相似文献/References:

[1]魏海梁 曹妮 李京涛 闫曙光 司明明 鞠迪.基于miRNA-124探讨益脾养肝方对大鼠肝癌前病变影响的实验研究[J].陕西中医药大学学报,2020,(5):060.[doi:10.13424/j.cnki.jsctcm.2020.05.016]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金项目（81904192）；陕西省教育厅项目（19JK0244）；陕西中医药大学科学研究计划项目（2017QN15）；陕西中医药大学学科创新团队项目（2019-YS06）；陕西省自然科学基础研究计划青年项目(2022JQ-793，2022JQ-870)；陕西省中医药管理局项目（15-JC004）
更新日期/Last Update: 2024-03-29